Reduced Skeletal Muscle Uncoupling Protein-3 Content in Prediabetic Subjects and Type 2 Diabetic Patients: Restoration by Rosiglitazone Treatment
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
CONTEXT: The mitochondrial uncoupling protein-3 (UCP3) has been implicated in the protection of the mitochondrial matrix against lipid-induced mitochondrial damage. Recent evidence points toward mitochondrial aberrations as a major contributor to the development of insulin resistance and diabetes, and UCP3 is reduced in diabetes. OBJECTIVE: We compared skeletal muscle UCP3 protein levels in prediabetic subjects [i.e. impaired glucose tolerance (IGT)], diabetic patients, and healthy controls and examined whether rosiglitazone treatment was able to restore UCP3. PATIENTS, DESIGN, INTERVENTION: Ten middle-aged obese men with type 2 diabetes mellitus [age, 61.4 +/- 3.1 yr; body mass index (BMI), 29.8 +/- 2.9 kg/m(2)], nine IGT subjects (age, 59.0 +/- 6.6 yr; BMI, 29.7 +/- 3.0 kg/m(2)), and 10 age- and BMI-matched healthy controls (age, 57.3 +/- 7.4 yr; BMI, 30.1 +/- 3.9 kg/m(2)) participated in this study. After baseline comparisons, diabetic patients received rosiglitazone (2 x 4 mg/d) for 8 wk. MAIN OUTCOME MEASURES: Muscle biopsies were sampled to determine UCP3 and mitochondrial protein (complex I-V) content. RESULTS: UCP3 protein content was significantly lower in prediabetic IGT subjects and in diabetic patients compared with healthy controls (39.0 +/- 28.5, 47.2 +/- 24.7, and 72.0 +/- 23.7 arbitrary units, respectively; P < 0.05), whereas the levels of the mitochondrial protein complex I-V were similar between groups. Rosiglitazone treatment for 8 wk significantly increased insulin sensitivity and muscle UCP3 content (from 53.2 +/- 29.9 to 66.3 +/- 30.9 arbitrary units; P < 0.05). CONCLUSION: We show that UCP3 protein content is reduced in prediabetic subjects and type 2 diabetic patients. Eight weeks of rosiglitazone treatment restores skeletal muscle UCP3 protein in diabetic patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dysfunction of Mitochondria in Human Skeletal Muscle in Type 2 Diabetes
Kelley, D. E., He, J., Menshikova, E. V., & Ritov, V. B. (2002) · Diabetes · doi:10.2337/diabetes.51.10.2944 · Cited by 2,321
Diet, muscle glycogen and physical performance.
Bergström, J., Hermansen, L., Hultman, E., & Saltin, B. (1967) · Acta Physiologica Scandinavica · doi:10.1111/j.1748-1716.1967.tb03720.x · Cited by 1,740
McGarry, J. D. (2002) · Diabetes · doi:10.2337/diabetes.51.1.7 · Cited by 1,435
A signalling role for 4‐hydroxy‐2‐nonenal in regulation of mitochondrial uncoupling
Echtay, K. S., Esteves, T. C., Pakay, J. L., Jekabsons, M. B., Lambert, A. J., Portero‐Otín, M., Pamplona, R., Vidal‐Puig, A. J., Wang, S., Roebuck, S. J., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg412 · Cited by 597
Oxidative Capacity, Lipotoxicity, and Mitochondrial Damage in Type 2 Diabetes
Schrauwen, P., & Hesselink, M. K. C. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1412 · Cited by 408
Self-citationBRAND, M. D., PAMPLONA, R., PORTERO-OTÍN, M., REQUENA, J. R., ROEBUCK, S. J., BUCKINGHAM, J. A., CLAPHAM, J. C., & CADENAS, S. (2002) · Biochemical Journal · doi:10.1042/bj20021077 · Cited by 184
SCHRAUWEN, P., SARIS, W. H. M., & HESSELINK, M. K. C. (2001) · The FASEB Journal · doi:10.1096/fj.01-0400hyp · Cited by 172
Self-citationRussell, A. P., Gastaldi, G., Bobbioni-Harsch, E., Arboit, P., Gobelet, C., Dériaz, O., Golay, A., Witztum, J. L., & Giacobino, J.-P. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00875-5 · Cited by 166
Uncoupling protein 3 content is decreased in skeletal muscle of patients with type 2 diabetes
Schrauwen, P., Hesselink, M. K. C., Blaak, E. E., Borghouts, L. B., Schaart, G., Saris, W. H. M., & Keizer, H. A. (2001) · Diabetes · doi:10.2337/diabetes.50.12.2870 · Cited by 112
Self-citationHesselink, M. K. C., Greenhaff, P. L., Constantin-Teodosiu, D., Hultman, E., Saris, W. H. M., Nieuwlaat, R., Schaart, G., Kornips, E., & Schrauwen, P. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16653 · Cited by 82
Self-citation
Cited by
Mitochondrial uncoupling, ROS generation and cardioprotection
Cadenas, S. (2018) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2018.05.019 · Cited by 591
Mitochondrial respiration is decreased in skeletal muscle of patients with type 2 diabetes
Mogensen, M., Sahlin, K., Fernström, M., Glintborg, D., Vind, B. F., Beck-Nielsen, H., & Højlund, K. (2007) · Diabetes · doi:10.2337/db06-0981 · Cited by 573
“This is in contrast to a recent study showing a decreased UCP3 content in type 2 diabetic patients (50), probably due to different matching of the study subjects with respect to age, body composition, and physical activity.”
ResultPathological aspects of lipid peroxidation
Negre-Salvayre, A., Auge, N., Ayala, V., Basaga, H., Boada, J., Brenke, R., Chapple, S., Cohen, G., Feher, J., Grune, T., et al. (2010) · Free Radical Research · doi:10.3109/10715762.2010.498478 · Cited by 449
Meex, R. C. R., Schrauwen-Hinderling, V. B., Moonen-Kornips, E., Schaart, G., Mensink, M., Phielix, E., van de Weijer, T., Sels, J.-P., Schrauwen, P., & Hesselink, M. K. C. (2010) · Diabetes · doi:10.2337/db09-1322 · Cited by 355
Self-citationSchrauwen-Hinderling, V. B., Kooi, M. E., Hesselink, M. K. C., Jeneson, J. A. L., Backes, W. H., van Echteld, C. J. A., van Engelshoven, J. M. A., Mensink, M., & Schrauwen, P. (2007) · Diabetologia · doi:10.1007/s00125-006-0475-1 · Cited by 304
“In this context it is important to note that we recently found that mitochondrial protein content did not differ between patients with type 2 diabetes and BMImatched controls when a population similar to that participating in the current study was investigated [31].”
ResultSelf-citationMitochondrial dysfunction and lipotoxicity
Schrauwen, P., Schrauwen-Hinderling, V., Hoeks, J., & Hesselink, M. K. C. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.09.011 · Cited by 268
Heilbronn, L. K., Gan, S. K., Turner, N., Campbell, L. V., & Chisholm, D. J. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2210 · Cited by 184
Peroxisome Proliferator-Activated Receptor Expression Is Reduced in Skeletal Muscle in COPD
Remels, A. H., Schrauwen, P., Broekhuizen, R., Willems, J., Kersten, S., Gosker, H. R., & Schols, A. M. (2007) · European Respiratory Journal · doi:10.1183/09031936.00144106 · Cited by 168
“Moreover, SCHRAUWEN et al. [ 25 ] reported that administration of rosiglitazone, a potent PPAR-c agonist, restored muscular UCP3 levels in diabetic patients.”
BackgroundSelf-citationMensink, M., Hesselink, M. K. C., Russell, A. P., Schaart, G., Sels, J.-P., & Schrauwen, P. (2007) · International Journal of Obesity · doi:10.1038/sj.ijo.0803567 · Cited by 160
Self-citationHoeks, J., van Herpen, N. A., Mensink, M., Moonen-Kornips, E., van Beurden, D., Hesselink, M. K. C., & Schrauwen, P. (2010) · Diabetes · doi:10.2337/db10-0519 · Cited by 156
Self-citationHigh-fat diet, muscular lipotoxicity and insulin resistance
Schrauwen, P. (2007) · Proceedings of the Nutrition Society · doi:10.1017/s0029665107005277 · Cited by 153
“Finally, it has recently been shown (Schrauwen et al. 2006) that the insulin-sensitizing agent Rosiglitazone up regulates the protein content of UCP3 in skeletal muscle of patients with type 2 diabetes, in parallel with an improved oxidative capacity, mitochondrial succinate dehydrogenase activity…”
BackgroundSelf-citationThe Role of Mitochondria in the Pathophysiology of Skeletal Muscle Insulin Resistance
Pagel-Langenickel, I., Bao, J., Pang, L., & Sack, M. N. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0003 · Cited by 154
“down-regulated in T2DM subjects (200) and conversely”
The regulation and turnover of mitochondrial uncoupling proteins
Azzu, V., Jastroch, M., Divakaruni, A. S., & Brand, M. D. (2010) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2010.02.035 · Cited by 146
“Treatment of human patients with rosiglitazone upregulates UCP3 expression and improves insulin resistance in diabetic patients [103].”
BackgroundWijers, S. L. J., Schrauwen, P., Saris, W. H. M., & van Marken Lichtenbelt, W. D. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001777 · Cited by 135
Self-citationRespiratory uncoupling in skeletal muscle delays death and diminishes age-related disease
Gates, A. C., Bernal-Mizrachi, C., Chinault, S. L., Feng, C., Schneider, J. G., Coleman, T., Malone, J. P., Townsend, R. R., Chakravarthy, M. V., & Semenkovich, C. F. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.010 · Cited by 94
Mitochondrial Dysfunction in Skeletal Muscle Pathologies
Abrigo, J., Simon, F., Cabrera, D., Vilos, C., & Cabello-Verrugio, C. (2019) · Current Protein & Peptide Science · doi:10.2174/1389203720666190402100902 · Cited by 88
Contribution of the Mitochondria to Locomotor Muscle Dysfunction in Patients with COPD
Taivassalo, T., & Hussain, S. N. A. (2016) · Chest · doi:10.1016/j.chest.2015.11.021 · Cited by 59
Role of lipid-derived mediators in skeletal muscle insulin resistance
Taube, A., Eckardt, K., & Eckel, J. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00241.2009 · Cited by 40
Metadata
- Authors
- Schrauwen, P., Mensink, M., Schaart, G., Moonen-Kornips, E., Sels, J.-P., Blaak, E. E., Russell, A. P., & Hesselink, M. K. C.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-04-01
- Volume
- 91
- Issue
- 4
- Pages
- 1520-1525
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2005723843
- Cited by
- 70
- References
- 10
- FWCI
- 3.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.